Ellevest Inc’s Aurinia Pharmaceuticals AUPH Stock Holding History

Ellevest Inc’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2	Closed	-$22	–	468
2023 Q1	$22	Buy	+2	New	+$18	﹤0.01%	1844

Other funds holding AUPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Ellevest Inc's AUPH Position: Q2 2023 in Review

Ellevest Inc sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2023, closing a stake of 2 shares — an estimated $22 sold.

Ellevest Inc first reported a position in AUPH in Q1 2023 and held it in 1 quarter. The position peaked at $22 in Q1 2023. 200 funds tracked by Wall St. Rank hold AUPH as of Q2 2023.

Ellevest Inc reported no remaining Aurinia Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Ellevest Inc sold 2 Aurinia Pharmaceuticals shares in Q2 2023, an estimated $22.
Ellevest Inc first reported a position in Aurinia Pharmaceuticals in Q1 2023 and held it in 1 quarter.
Ellevest Inc's Aurinia Pharmaceuticals position peaked at $22 in Q1 2023.
200 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2023.

Based on Ellevest Inc's 13F filing for Q2 2023, filed 9 Aug 2023.